Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03038477
Title A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver
Indications

pancreatic ductal adenocarcinoma

Therapies

Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.